Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings.
Pestchanker C, Bertado Cortez B, Lana Peixoto MA, Gortari JI, Castro Suarez S, Caparo Zamalloa C, Galiana G, Peñalver F, Daccach Marques V, Messias K, Galleguillos L, García F, Rojas JI, Patrucco L, Cristiano E, Tkachuk V, Liwacki S, Correale J, Marrodan M, Ysraelit MC, Vrech C, Deri N, Leguizamon F, Tavolini D, Mainella C, Zanga G, Alonso Serena M, Ciampi E, Neto HRS, Lopez P, Carnero Contentti E. Pestchanker C, et al. Among authors: penalver f. J Neurol. 2024 Apr 17. doi: 10.1007/s00415-024-12371-8. Online ahead of print. J Neurol. 2024. PMID: 38630312
Management of Persistent SARS-CoV-2 Infection in Patients with Follicular Lymphoma.
Martínez-Barranco P, García-Roa M, Trelles-Martínez R, Arribalzaga K, Velasco M, Guijarro C, Marcos J, Campelo C, Acedo-Sanz JM, Villalón L, Ricard P, García-Bueno MJ, Pérez-Fernández E, Rodríguez-Caravaca G, Peñalver FJ. Martínez-Barranco P, et al. Among authors: penalver fj. Acta Haematol. 2022;145(4):384-393. doi: 10.1159/000521121. Epub 2021 Nov 26. Acta Haematol. 2022. PMID: 34839289 Free PMC article.
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
González-Rincón J, Garcia-Vela JA, Gómez S, Fernández-Cuevas B, Nova-Gurumeta S, Pérez-Sanz N, Alcoceba M, González M, Anguita E, López-Jiménez J, González-Barca E, Yáñez L, Pérez-Persona E, de la Serna J, Fernández-Zarzoso M, Deben G, Peñalver FJ, Fernández MC, de Oteyza JP, Andreu MÁ, Ruíz-Guinaldo MÁ, Paz-Arias R, García-Malo MD, Recasens V, Collado R, Córdoba R, Navarro-Matilla B, Sánchez-Beato M, García-Marco JA. González-Rincón J, et al. Among authors: penalver fj. PLoS One. 2021 Sep 10;16(9):e0257353. doi: 10.1371/journal.pone.0257353. eCollection 2021. PLoS One. 2021. PMID: 34506616 Free PMC article.
Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study.
Regalado-Artamendi I, Jiménez-Ubieto A, Hernández-Rivas JÁ, Navarro B, Núñez L, Alaez C, Córdoba R, Peñalver FJ, Cannata J, Estival P, Quiroz-Cervantes K, Riaza Grau R, Velasco A, Martos R, Domingo-González A, Benito-Parra L, Gómez-Sanz E, López-Jiménez J, Matilla A, Herraez MR, Penalva MJ, García-Suárez J, Díez-Martín JL, Bastos-Oreiro M. Regalado-Artamendi I, et al. Among authors: penalver fj. Hemasphere. 2021 Feb 10;5(3):e538. doi: 10.1097/HS9.0000000000000538. eCollection 2021 Mar. Hemasphere. 2021. PMID: 33604516 Free PMC article.
R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group.
Sancho JM, Fernández-Alvarez R, Gual-Capllonch F, González-García E, Grande C, Gutiérrez N, Peñarrubia MJ, Batlle-López A, González-Barca E, Guinea JM, Gimeno E, Peñalver FJ, Fuertes M, Bastos M, Hernández-Rivas JÁ, Moraleda JM, García O, Sorigué M, Martin A. Sancho JM, et al. Among authors: penalver fj. Cancer Med. 2021 Feb;10(4):1314-1326. doi: 10.1002/cam4.3730. Epub 2021 Jan 25. Cancer Med. 2021. PMID: 33492774 Free PMC article. Clinical Trial.
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
Peñalver FJ, Márquez JA, Durán S, Giraldo P, Martín A, Montalbán C, Sancho JM, Ramírez MJ, Terol MJ, Capote FJ, Gutiérrez A, Sánchez B, López A, Salar A, Rodríguez-Caravaca G, Canales M, Caballero MD; GELTAMO (The Spanish Lymphoma Cooperative Group). Peñalver FJ, et al. Cancer Med. 2019 Nov;8(16):6955-6966. doi: 10.1002/cam4.2555. Epub 2019 Oct 1. Cancer Med. 2019. PMID: 31573746 Free PMC article. Clinical Trial.
44 results